7-nitroso-3-(trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine

1 Results Found

Sitagliptin is an orally available, competitive, beta-amino acid-derived inhibitor of dipeptidyl peptidase 4 (DDP-4) with hypoglycemic activity. Sitagliptin may cause an increased risk in the development of pancreatitis. (Ref. NCI Thesaurus (NCIt) )
Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor which is used in combination with diet and exercise in the therapy of type 2 diabetes, either alone or in combination with other oral hypoglycemic agents. (Ref. LiverTox)
Sitagliptin is a triazolopyrazine that exhibits hypoglycemic activity. It has a role as a serine proteinase inhibitor, a hypoglycemic agent, an EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor, an environmental contaminant and a xenobiotic. It is a triazolopyrazine and a trifluorobenzene. (Ref.Pub chem)

Sitagliptin API Reference standards and its EP Impurities, USP Impurities, non pharmacopeial Impurities, listed below & also offered custom synthesis for unknown Impurities. If require for any degradation Impurities contact info@drjcrbio.com, sales@drjcrbio.com

• Page 1 of 1
• 1